All Articles
Sep 13, 2021

Pier Vincenzo Piazza, CEO of Aelis Farma, was invited to give a plenary lecture at the meeting of the Italian Society for neuroscience

Bordeaux, France, September 13th, 2021 – On September 11, 2021, Pier Vincenzo Piazza, CEO of Aelis Farma, was invited to give a plenary lecture at the meeting of the Italian Society for neuroscience on the discovery and properties of the new class of drugs developed by Aelis Farma: the CB1 SSi. Many thanks to Pr. Alessandro Usiello and SINS for the real privilege to share our progress with such an outstanding audience of more than 1000 delegates.

Dr. Piazza said: “Special thanks to Pr. Alessandro Usiello for the too kind introduction I am honored and it has been a real privilege to share our progress with such an outstanding audience of more than 1000 delegates.”

About AELIS FARMA
AELIS FARMA is a clinical-stage biotechnology company founded in 2014 as a spin-off of the Magendie Neurocenter in Bordeaux, a leading Neuroscience institute of INSERM (French National Institute of Health and Medical Research) and University of Bordeaux. AELIS FARMA’s mission is to develop a new pharmacological drug class, the Signaling Specific inhibitors of the CB1 receptor (CB1-SSI) that were discovered by the research team of Dr. Pier Vincenzo Piazza, the Company’s CEO, during his tenure as director of the Magendie Institute. For this discovery Dr. Piazza was awarded the Grand Prix of INSERM and the Grand Prix of Neurology of the French Academy of Science that are among the most prestigious French scientific awards.

CB1-SSi have potential application for the treatment of numerous disorders. The Company is currently developing two first-in-class drug candidates: AEF0117, and AEF0217.

AEF0117, which targets cannabis related disorders (CUD and psychosis), has been studied in a Phase IIa trial in subjects with cannabis use disorders and was performed at Columbia University (NY, USA) and shown positive signs of efficacy; it will now enter into a Phase IIb trial.

AEF0217, which is being developed for the treatment of cognitive impairments, will enter Phase I clinical trials in the second half of 2021 and will be first tested as a therapy of cognitive deficits in Down syndrome.

AELIS FARMA also has a CB1-targeted Platform that has already generated novel leads with differentiated pharmacological characteristics.

AELIS FARMA has its headquarter at the Magendie Neurocenter in Bordeaux and has received grants and/or investments from the Nouvelle-Aquitaine region, the European Union, NIDA (National Institute on Drug Abuse, NIH, USA), Inserm Transfert Initiative, Bpifrance, Aquiti, NACO and Irdi Capital Investissement.